Tag: valproic acid

New JAMA Study Challenges Previous Concerns About Valproate and Paternal Risk

What we thought we knew may not hold up under scrutiny.

A recent JAMA Psychiatry study titled “Disorders and Paternal Use of Valproate During Spermatogenesis” has delivered surprising news:

There was no increased risk of neurodevelopmental disorders in children whose fathers were taking valproic acid around the time of conception.

This finding directly challenges earlier observational data that suggested a possible link, leading to cautionary guidance against prescribing valproate to men of reproductive age. But now, with a large, well-conducted study showing no signal of harm, we’re left reconsidering that initial recommendation.

As clinicians, we must remember:
🔍 Association is not causation.
🚧 Observational studies, while valuable, can mislead when confounding variables aren’t fully accounted for.
📚 Evidence evolves—and so must our clinical guidance.

This study not only impacts how we think about valproate use in men but also serves as a critical reminder about the limits of inference from non-randomized data.

👉 For patients with bipolar disorder or epilepsy who benefit from valproate, this offers some reassurance. We may not need to withhold an effective treatment based on unconfirmed reproductive risks.

📌 Bottom line: Always be skeptical. Always be curious. Always be willing to revise your practice when the data say it’s time.

link to the study: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2834363

0

💥 Time to Rethink Valproate in Acute Mania

Valproate continues to be overvalued in the treatment of acute mania—and it doesn’t work as well as many assume.

Part of the problem? A single overhyped study, cleverly marketed by the pharmaceutical company, has shaped decades of prescribing habits and continues to be taught to psychiatry residents as gold-standard evidence.

But the data tells a different story.
The BALANCE study (British study of Lithium +/− Valproate) showed no significant long-term benefit to adding valproate to lithium over a 2-year period in bipolar disorder.

It’s time we stop relying on outdated assumptions and start practicing based on robust, long-term outcomes—not industry narratives.

📚 Evidence over tradition.
🧠 Teach residents the full picture.
💊 Prescribe with precision.

0

Is olanzapine overrated for acute mania?

🧠 Olanzapine has built a reputation as a heavy-hitter for treating acute manic episodes—but the data tells a more modest story.

In one key study comparing olanzapine vs. placebo over 3 weeks:

  • Response rate: 55% (olanzapine) vs. 30% (placebo)
  • Remission rate: 18% (olanzapine) vs. 7% (placebo)

That’s a 25% absolute difference in response and just an 11% difference in remission—not exactly blockbuster results.

This doesn’t mean olanzapine has no role in mania treatment. But it’s time to recalibrate our expectations and remain clear-eyed about what the data shows.

💊 Efficacy matters. So does the narrative we build around our tools.

0

Powered by WordPress.com.

Up ↑